Propofol GABA Modulation for Refractory Insomnia Sleep Stages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical treatments for acute and chronic insomnia are ineffective for individuals with severe sleep deprivation disorders, as they fail to adequately target the GABA receptors necessary for achieving restorative N3/NREM sleep.
Innovation Solution
Medically supervised administration of Diprivan/Propofol, which positively modulates GABA receptors to induce rapid and temporary progression through sleep cycles, enhancing GABAergic inhibition and promoting deep sleep states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical treatments are used for insomnia, then mild sleep improvement may be achieved, but they are ineffective for severe sleep deprivation disorders and fail to achieve restorative N3/NREM sleep
Solution Approach 1:
The patent changes the pharmacological parameter by using Diprivan/Propofol, an anesthetic agent with potent GABAergic activity, instead of conventional insomnia medications. This parameter change enables the treatment to achieve restorative N3/NREM sleep in severe cases where conventional treatments fail, directly resolving the contradiction between treatment reliability and adaptability to severe conditions
2Speed
If Diprivan/Propofol is administered to induce rapid progression through sleep cycles, then restorative sleep is achieved quickly, but the treatment requires medically supervised administration
Solution Approach 1:
The patent implements preliminary action by requiring pre-treatment medical evaluation, patient screening, and establishment of medically supervised protocols before Diprivan/Propofol administration. This preliminary preparation enables the rapid induction of restorative sleep while managing the complexity through structured pre-procedural steps, resolving the contradiction between speed of effect and administrative complexity
3Loss of time
If conventional treatments are used for chronic insomnia, then treatment duration is extended, but they fail to provide rapid relief from severe sleep deprivation
Solution Approach 1:
The patent employs periodic action by administering Diprivan/Propofol in controlled, repeated sessions rather than continuous conventional medication. Each session rapidly induces restorative sleep, and the periodic nature of treatment allows cumulative therapeutic effects while providing rapid relief between sessions, resolving the contradiction between time to relief and duration of treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Diprivan/Propofol allows individuals to quickly enter and maintain restorative N2/N3 sleep stages, providing rapid relief from sleep deprivation with minimal recovery time, making it a unique and effective treatment for refractory chronic insomnia.
Implementation Method 1
Diprivan/Propofol, which positively modulates GABA receptors to induce rapid and temporary progression through sleep cycles, enhancing GABAergic inhibition and promoting deep sleep states
Data Source
AI summary
A method of treatment for individuals suffering from chronic primary or secondary refractory chronic insomnia by administration of Diprivan/Propofol, to move a patient through the stages of sleep such that the patient obtains sufficient adequate rest.